Moderna tops CNBC's list of most disruptive new technologies

Promising preclinical work on messenger RNA therapies has provided Moderna Therapeutics with the number one spot on CNBC's list of the most disruptive new technologies now in the spotlight. The company has raised close to a billion dollars and partnered with companies like Merck ($MRK) to advance a portfolio of nearly 50 preclinical programs. The big idea here is that mRNA can be used to code cells to make the antibodies and proteins needed to fight a multitude of diseases. And investors are all in. Story

Suggested Articles

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.

Dutch scientists used stem cells from CF patients to demonstrate a technique that corrects a mutation in the gene CFTR without having to cut DNA.

A new map of the thymus gland could help researchers understand how T cells develop and inspire treatments for cancer and autoimmune disease.